Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer
Abstract
Genomic biomarkers that predict response to anti-PD1 therapy in prostate cancer are needed. Frameshift mutations are predicted to generate more neoantigens than missense mutations; therefore, we hypothesized that the number or proportion of tumor frameshift mutations would correlate with response to anti-PD1 therapy in prostate cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Dec 03, 2020
- Source ID
- 10.1002/onco.13601
Entities
People
- Alan H. Bryce
- Amanda C. Larson
- Benjamin L. Maughan
- Colin C Pritchard
- Drew M Pardoll
- Emily Nizialek
- Emmanuel S. Antonarakis
- Hao Wang
- James R. Eshleman
- Julia Fountain
- Laura A. Sena
- Miguel Gonzalez Velez
- Nabil Adra
- Neeraj Agarwal
- Nityam Rathi
- Pedro Isaacsson Velho
- Roberto H Nussenzveig
- Ryan Ashkar
- Su Jin Lim
- Tamara L Lotan
Organizations
- Indiana University
- Johns Hopkins University
- Mayo Clinic
- National Institutes of Health
- University of Utah
- University of Washington